Third Harmonic Bio, Inc. has completed an IPO in the amount of $185.3 million.
September 14, 2022 at 09:30 am IST
Share
Third Harmonic Bio, Inc. has completed an IPO in the amount of $185.3 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 10,900,000
PriceRange: $17
Discount Per Security: $1.19
Transaction Features: Sponsor Backed Offering
Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.
THIRD HARMONIC BIO, INC. 
